
CLAIMS

1. A compound of Formula (IVf),



(IVf)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen, fluoro, chloro or methyl;

X is N or CH;

R^3 is halo, cyano, $C_{1\text{-}3}$alkyl, or halo$C_{1\text{-}3}$alkyl;

R^4 is hydrogen, halo, cyano, $C_{1\text{-}3}$alkyl or halo$C_{1\text{-}3}$alkyl;

R^5 is halo, $C_{1\text{-}3}$alkyl, $C_{3\text{-}5}$cycloalkyl, halo$C_{1\text{-}3}$alkyl, halo$C_{1\text{-}3}$alkoxy or $C_{1\text{-}3}$alkoxy;

R^6 is halo, cyano, $C_{1\text{-}3}$alkyl, $C_{3\text{-}5}$cycloalkyl, halo$C_{1\text{-}3}$alkyl, $C_{1\text{-}3}$alkoxy or halo$C_{1\text{-}3}$alkoxy;

R^{11} is each independently halo;

k is 0, 1, 2 or 3;

m is 0, 1 or 2; and

n is 0, 1 or 2.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen, fluoro, chloro or methyl;

X is N or CH;

R^3 is halo, cyano, $C_{1\text{-}3}$alkyl, or halo$C_{1\text{-}3}$alkyl;


R^4 is hydrogen, halo, cyano, $C_{1\text{-}3}$alkyl or halo$C_{1\text{-}3}$alkyl;

R^5 is halo, C_{1-3}alkyl, C_{3-5}cycloalkyl, haloC_{1-3}alkyl, haloC_{1-3}alkoxy or C_{1-3}alkoxy;
R^6 is halo, cyano, C_{1-3}alkyl, C_{3-5}cycloalkyl, haloC_{1-3}alkyl, C_{1-3}alkoxy or haloC_{1-3}alkoxy;
R^{11} is fluoro;
k is 0, 1, 2 or 3;
m is 0, 1 or 2; and
n is 0, 1 or 2.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein k is 0;
m is 1; and
n is 1.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein
R^1 is hydrogen, fluoro or chloro;
X is CH;
R^4 is hydrogen, fluoro, chloro or methyl;
R^5 is methoxy or cyclopropyl;
R^6 is methyl; and
R^{11} is fluoro.


5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, having the Formula (IVl)




(IVl)

wherein R^{11a} and R^{11b} are each fluoro.


6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:




,



,




, and



.

7. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein the compound is



.

8. A pharmaceutical composition comprising a compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9. A compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 8, for use in medicine.

10. Use of a compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 8, in the manufacture of a medicament for the treatment or prevention of a disease or disorder associated with complement factor B (CFB), wherein the disease or disorder is selected from multiple sclerosis, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino- choroiditis, sympathetic ophthalmia, ocular cicatricial pemphigoid, ocular pemphigus, nonarteritic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, stroke, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, neural regeneration, dyspnea, hemoptysis, ARDS, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, immune complex-associated inflammation, antiphospholipid syndrome, glomerulonephritis, obesity and metabolic syndrome.

11. The use according to claim 10, wherein the disease or disorder is selected from kidney disease, chronic kidney disease, diabetic nephropathy, glomerular kidney disease, complement C3 glomerulopathy (C3G), IgA nephropathy (IgAN), membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS), atypical hemolytic uremic syndrome (aHUS), dense-deposit disease (DDD), minimal change disease (MCD), paroxysmal nocturnal hemoglobinuria (PNH), ANCA-associated vasculitis, lupus nephritis and polycystic kidney disease (PKD).